CAL 101 - Calluna Pharma
Alternative Names: CAL-101 - Calluna PharmaLatest Information Update: 04 Mar 2024
At a glance
- Originator Calluna Pharma
- Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies
- Mechanism of Action S100 calcium-binding protein A4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fibrosis; Inflammation
Most Recent Events
- 23 Jan 2024 Phase-I clinical trials in Fibrosis (Parenteral) prior to January 2024 (Calluna Pharma pipeline, January 2024)
- 23 Jan 2024 Phase-I clinical trials in Inflammation (Parenteral) prior to January 2024 (Calluna Pharma pipeline, January 2024)
- 23 Jan 2024 Preclinical trials in Inflammation in Norway prior to January 2024 (Parenteral)